Søgeord (influenza) valgt.
98 emner vises.
1
Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19
Tadashi HosoyaSeiya ObaYoji KomiyaDaisuke KawataMari KamiyaHideyuki IwaiSho MiyamotoMichiyo KataokaMinoru TobiumeTakayuki KannoAkira AinaiHiroyuki SatoAkihiro HirakawaYuichi MitsuiTakashi SatohKenji WakabayashiTetsuya YamadaYasuhiro OtomoYasunari MiyazakiHideki HasegawaTadaki SuzukiShinsuke YasudaaDepartment of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapanbDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 208-0011, JapancDepartment of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapandDepartment of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapaneDepartment of Intensive Care Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapanfDepartment of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapangTrauma and Acute Critical Care Medical Center, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapanhDepartment of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapaniCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan
Proceedings of the National Academy of Sciences, 31.05.2023
Tilføjet 31.05.2023
2
Influenza-associated neurologic complications in children from an H3N2 outbreak in Shenzhen, China during COVID-19 lockdown
Ruimu Zhang, Jialun Wen, Kai Wu, Sufang Lin, Kun Tan, Jiajia Bi, Jikui Deng
International Journal of Infectious Diseases, 30.05.2023
Tilføjet 30.05.2023
Influenza is an acute respiratory infection caused by influenza viruses that circulate worldwide. The annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 290 000 to 650 000 respiratory deaths in the world [1]. In addition, 4.8%-18.9% of children with influenza develop various neurologic complications, including febrile seizure, influenza-associated encephalopathy/encephalitis, transverse myelitis, Guillain-Barré syndrome, and Reye\'s syndrome [2, 3].
Læs mere
Tjek på PubMed
3
High-dose influenza vaccine is associated with reduced mortality among older adults with breakthrough influenza even when there is poor vaccine-strain match
Clinical Infectious Diseases, 29.05.2023
Tilføjet 29.05.2023
AbstractBackgroundHigh-dose (HD) influenza vaccine offers improved protection from influenza virus infection among older adults compared with standard-dose (SD) vaccine. Here we explored whether HD vaccine attenuates disease severity among older adults with breakthrough influenza.MethodsRetrospective cohort study among adults ≥65 years from U.S. claims data, for seasons 2016-17, 2017-18 and 2018-19 defined as October 1st through April 30th. After adjusting the different cohorts for the probability of vaccination conditional on patients’ characteristics, we compared 30-day mortality rate post-influenza among older adults experiencing breakthrough infection after receipt of HD or SD influenza vaccines and among those not vaccinated (NV).ResultsWe evaluated 44,456 influenza cases: 23,109 (52%) were unvaccinated, 15,037 (33.8%) received HD vaccine and 6,310 (14.2%) received SD vaccine. Significant reductions in mortality rates among breakthrough cases were observed across all three seasons for HD vs NV, ranging from 17-29% reductions. A significant mortality reduction of 25% was associated with SD vaccination vs. NV in the 2016-17 season, when there was a good match between circulating influenza viruses and selected vaccine strains. When comparing HD vs. SD cohorts, mortality reductions were higher among those receiving HD in the last two seasons, when mismatch between vaccine strains and circulating H3N2 viruses were documented, albeit not significant.ConclusionHD vaccination was associated with lower post-influenza mortality among older adults with breakthrough influenza, even during seasons where antigenically drifted H3N2 circulated. Improved understanding of the impact of different vaccines on attenuating disease severity is warrant when assessing vaccine policy recommendations.
Læs mere
Tjek på PubMed
4
Streptococcus pyogenes colonization in children aged 24-59 months in The Gambia: Impact of Live Attenuated Influenza Vaccine and associated serological responses
Journal of Infectious Diseases, 29.05.2023
Tilføjet 29.05.2023
AbstractBackgroundImmunity to Streptococcus pyogenes in high burden settings is poorly understood. We explored S. pyogenes nasopharyngeal colonization after intranasal live attenuated influenza vaccine (LAIV) among Gambian children aged 24-59 months, and resulting serological response to 7 antigens.MethodsA post-hoc analysis was performed in 320 children randomized to receive LAIV at baseline (LAIV group) or not (control). S. pyogenes colonization was determined by quantitative Polymerase Chain Reaction (qPCR) on nasopharyngeal swabs from baseline (D0), day 7 (D7) and day 21 (D21). Anti-streptococcal IgG was quantified, including a subset with paired serum pre/post S. pyogenes acquisition.ResultsThe point prevalence of S. pyogenes colonization ranged from 7-13%. In children negative at D0, S. pyogenes was detected at D7 or D21 in 18% of LAIV group and 11% of control group participants (p=0.12). The odds ratio (OR) for colonization over time was significantly increased in the LAIV group (D21 vs D0 OR 3.18, p=0.003) but not in the control group (OR 0.86, p=0.79). The highest IgG increases following asymptomatic colonization were seen for M1 and SpyCEP proteins.ConclusionsAsymptomatic S. pyogenes colonization appears modestly increased by LAIV, and may be immunologically significant. LAIV could be used to study influenza-S. pyogenes interactions.
Læs mere
Tjek på PubMed
5
Reciprocal enhancement of SARS-CoV-2 and influenza virus replication in human pluripotent stem cell-derived lung organoids1
Min Jung Kim, Sumi Kim, Heeyeon Kim, Dayeon Gil, Hyeong-Jun Han, Rajesh K. Thimmulappa, Jang-Hoon Choi, Jung-Hyun Kim
Emerg Microbes Infect, 28.05.2023
Tilføjet 28.05.2023
6
Mixed selling of different poultry species facilitates emergence of public-health-threating avian influenza viruses
Zhen Wang, Hongkui Li, Yuhan Li, Zhuanli Wu, Hui Ai, Ming Zhang, Libin Rong, Michael L. Blinov, Qi Tong, Litao Liu, Honglei Sun, Juan Pu, Wenhai Feng, Jinhua Liu, Yipeng Sun
Emerg Microbes Infect, 26.05.2023
Tilføjet 26.05.2023
7
Cell-intrinsic genomic reassortment of pandemic H1N1 2009 and Eurasian avian-like swine influenza viruses results in potentially zoonotic variants
Verónica A. Ferrando, Marcel E. Friedrich, Shrey Gandhi, Alexander Mellmann, Dörthe Masemann, Anmari Christersson, Darisuren Anhlan, Linda Brunotte, Monika Stoll, Timm Harder, Martin Beer, Yvonne Boergeling, Stephan Ludwig
Emerg Microbes Infect, 26.05.2023
Tilføjet 26.05.2023
8
Influenza A virus exploits transferrin receptor recycling to enter host cells
Beryl Mazel-SanchezChengyue NiuNathalia WilliamsMichael BachmannHélèna CholtusFilo SilvaVéronique Serre-BeinierWolfram KarenovicsJustyna IwaszkiewiczVincent ZoeteLaurent KaiserOliver HartleyBernhard Wehrle-HallerMirco SchmolkeaDepartment of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, 1211 Geneva, SwitzerlandbDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, SwitzerlandcThoracic Surgery, Geneva University Hospitals, 1205 Geneva, SwitzerlanddMolecular Modeling Group, Swiss Institute of Bioinformatics, 1015 Lausanne, SwitzerlandeComputer-Aided Molecular Engineering Group, Department of Oncology (University of Lausanne and the Lausanne University Hospital), Ludwig Institute for Cancer Research Lausanne, 1066 Épalinges, SwitzerlandfDepartment of Medicine, Faculty of Medicine, University of Geneva, 1211 Geneva, SwitzerlandgGeneva Centre for Emerging Viral Diseases, Geneva University Hospitals, 1205 Geneva, SwitzerlandhDivision of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, SwitzerlandiDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, SwitzerlandjGeneva Center of Inflammation Research, University of Geneva, 1211 Geneva, Switzerland
Proceedings of the National Academy of Sciences, 24.05.2023
Tilføjet 24.05.2023
9
Changes in the epidemiological profile of SARS-CoV-2-positive individuals in Mexico across pandemic waves as an explanation of fatality reduction: a retrospective observational study
Gutierrez, J. P., Lopez, D., Ascencio, I., Juarez, A., Olaiz, G., Bertozzi, S. M.
BMJ Open, 23.05.2023
Tilføjet 23.05.2023
ObjectivesWe aim to quantify shifts in hospitalisation and mortality and how those were related to the first three phases of the epidemic and individuals’ demographics and health profile among those with a positive test for SARS-CoV-2 treated at the Mexican Social Security Institute’s facilities from March 2020 to October 2021. DesignRetrospective observational study using interrupted time series analysis to identify changes in hospitalisation rate and case fatality rate (CFR) by epidemic wave. SettingData from the Mexican Institute of Social Security’s (IMSS) Online Influenza Epidemiological Surveillance System (SINOLAVE) that include all individuals that sought care at IMSS facilities all over Mexico. ParticipantsAll individuals included in the SINOLAVE with a positive PCR or rapid test for SARS-CoV-2. Primary and secondary outcome measuresMonthly test positivity rates, hospitalisation rates, CFRs and prevalence of relevant comorbidities by age group. ResultsFrom March 2020 to October 2021, the CFR declined between 1% and 3.5%; the declines were significant for those 0–9, 20–29, 30–39, 40–49 and 70 and older. The decline was steep during the first wave and was less steep or was temporarily reversed at the beginning of the second and third waves (changes in the trend of about 0.3% and 3.8%, and between 0.7% and 3.8%, respectively, for some age groups), but then continued to the end of the analytical period. Prevalence of diabetes, hypertension and obesity among patients testing positive also declined—two for most age groups (reductions of up to 10 percentage points for diabetes, 12 percentage points for hypertension and 19 percentage points for obesity). ConclusionData suggest that the decrease in COVID-19 fatality rate is at least partially explained by a change in the profile of those contracting the disease, that is, a falling proportion of individuals with comorbidities across all age groups.
Læs mere
Tjek på PubMed
10
Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19
Tadashi HosoyaSeiya ObaYoji KomiyaDaisuke KawataMari KamiyaHideyuki IwaiSho MiyamotoMichiyo KataokaMinoru TobiumeTakayuki KannoAkira AinaiHiroyuki SatoAkihiro HirakawaYuichi MitsuiTakashi SatohKenji WakabayashiTetsuya YamadaYasuhiro OtomoYasunari MiyazakiHideki HasegawaTadaki SuzukiShinsuke YasudaaDepartment of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapanbDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 208-0011, JapancDepartment of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapandDepartment of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapaneDepartment of Intensive Care Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapanfDepartment of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapangTrauma and Acute Critical Care Medical Center, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapanhDepartment of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, JapaniCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan
Proceedings of the National Academy of Sciences: Immunology and Inflammation, 23.05.2023
Tilføjet 23.05.2023
11
Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles
Raphael J. Crum, Brydie R. Huckestien, Gaelen Dwyer, Lisa Mathews, David G. Nascari, George S. Hussey, Heth R. Turnquist, John F. Alcorn, Stephen F. Badylak
Science Advances, 20.05.2023
Tilføjet 20.05.2023
12
The attributable fraction of respiratory syncytial virus among patients of different age with influenza-like illness and severe acute respiratory illness in a high HIV prevalence setting, South Africa, 2012-2016
Jocelyn Moyes, Stefano Tempia, Sibongile Walaza, Meredith L. McMorrow, Adam L. Cohen, Florette Treurnicht, Orienka Hellferscee, Nicole Wolter, Anne Von Gottberg, Halima Dawood, Ebrahim Variava, Kathleen Kahn, Shabir A. Madhi, Cheryl Cohen
International Journal of Infectious Diseases, 20.05.2023
Tilføjet 20.05.2023
It is estimated that up to 33.1 million episodes of RSV-associated lower respiratory tract infection (LRTI) occur annually globally in children under-5 years of age, approximately 10% of which result in hospitalisation[1]. Of the nearly 120,000 estimated RSV-associated global deaths among children aged
Læs mere
Tjek på PubMed
13
Field-deployable multiplex detection method of SARS-CoV-2 and influenza virus using loop-mediated isothermal amplification and DNA chromatography
Kyoko Hayashida, Alejandro Garcia, Lavel Chinyama Moonga, Tatsuki Sugi, Kodera Takuya, Mitsuo Kawase, Fumihiro Kodama, Atsushi Nagasaka, Nobuhisa Ishiguro, Ayato Takada, Masahiro Kajihara, Naganori Nao, Masashi Shingai, Hiroshi Kida, Yasuhiko Suzuki, William W. Hall, Hirofumi Sawa, Junya Yamagishi
PLoS One Infectious Diseases, 16.05.2023
Tilføjet 16.05.2023
by Kyoko Hayashida, Alejandro Garcia, Lavel Chinyama Moonga, Tatsuki Sugi, Kodera Takuya, Mitsuo Kawase, Fumihiro Kodama, Atsushi Nagasaka, Nobuhisa Ishiguro, Ayato Takada, Masahiro Kajihara, Naganori Nao, Masashi Shingai, Hiroshi Kida, Yasuhiko Suzuki, William W. Hall, Hirofumi Sawa, Junya Yamagishi A novel multiplex loop-mediated isothermal amplification (LAMP) method combined with DNA chromatography was developed for the simultaneous detection of three important respiratory disease-causing viruses: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus, and influenza B virus. Amplification was performed at a constant temperature, and a positive result was confirmed by a visible colored band. An in-house drying protocol with trehalose was used to prepare the dried format multiplex LAMP test. Using this dried multiplex LAMP test, the analytical sensitivity was determined to be 100 copies for each viral target and 100–1000 copies for the simultaneous detection of mixed targets. The multiplex LAMP system was validated using clinical COVID-19 specimens and compared with the real-time qRT-PCR method as a reference test. The determined sensitivity of the multiplex LAMP system for SARS-CoV-2 was 71% (95% CI: 0.62–0.79) for cycle threshold (Ct) ≤ 35 samples and 61% (95% CI: 0.53–0.69) for Ct ≤40 samples. The specificity was 99% (95%CI: 0.92–1.00) for Ct ≤35 samples and 100% (95%CI: 0.92–1.00) for the Ct ≤40 samples. The developed simple, rapid, low-cost, and laboratory-free multiplex LAMP system for the two major important respiratory viral diseases, COVID-19 and influenza, is a promising field-deployable diagnosis tool for the possible future ‘twindemic, ‘ especially in resource-limited settings.
Læs mere
Tjek på PubMed
14
End-of-season influenza vaccine effectiveness during the Southern Hemisphere 2022 Influenza Season – Chile, Paraguay, and Uruguay
Anna N. Chard, Francisco Nogareda, Annette K. Regan, María Fernanda Olivares Barraza, Rodrigo A. Fasce, Natalia Vergara, Marcela Avendaño, Elena Penayo, Cynthia Vázquez, Marta Von Horoch, Fabiana Michel, Adriana Alfonso, Cristina Mogdasy, Hector Chiparelli, Natalia Goñi, Miguel Alegretti, Sergio Loayza, Paula Couto, Angel Rodriguez, Daniel Salas, Ashley L. Fowlkes, Eduardo Azziz-Baumgartner
International Journal of Infectious Diseases, 16.05.2023
Tilføjet 16.05.2023
Influenza vaccine composition is reviewed and updated bi-annually to ensure optimal vaccine effectiveness for the Northern and Southern Hemispheres [1]. Influenza viruses circulating in the Southern Hemisphere can provide early indications of the effectiveness of antigens retained in subsequent Northern Hemisphere formulations for preventing severe illness [2]. Timely provision of Southern Hemisphere end-of-season vaccine effectiveness (VE) estimates have important implications for public health policy in these countries and are especially valuable while Northern Hemisphere influenza epidemics are ongoing, but surveillance systems have yet to identify enough cases to reliably estimate VE.
Læs mere
Tjek på PubMed
15
WHO: Confirmed Avian Influenza Death in China
Journal of the American Medical Association, 16.05.2023
Tilføjet 16.05.2023
A person in China was infected with avian influenza A(H3N8) virus in February, the nation’s health agency reported to the World Health Organization (WHO). The patient died after being hospitalized for severe pneumonia.
Læs mere
Tjek på PubMed
16
Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in 2022-2023
Journal of the American Medical Association, 16.05.2023
Tilføjet 16.05.2023
This study uses data from the US Department of Veterans Affairs to assess whether SARS-CoV-2 remains associated with higher risk of death compared with seasonal influenza in fall-winter 2022-2023.
Læs mere
Tjek på PubMed
17
Baicalin inhibits influenza A (H1N1)‐induced pyroptosis of lung alveolar epithelial cells via caspase‐3/GSDME pathway
Zhenqiao Wei, Rui Gao, Zhen Sun, Wen Yang, Qi He, Chenhui Wang, Jingxiang Zhang, Xiaochang Zhang, Liang Guo, Shengqi Wang
Journal of Medical Virology, 16.05.2023
Tilføjet 16.05.2023
18
Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
Sathya N. Thulasi Raman, Adrian Zetner, Anwar M. Hashem, Devina Patel, Jianguo Wu, Caroline Gravel, Jun Gao, Wanyue Zhang, Annabelle Pfeifle, Levi Tamming, Karan Parikh, Jingxin Cao, Roger Tam, David Safronetz, Wangxue Chen, Michael J.W. Johnston, Lisheng Wang, Simon Sauve, Michael Rosu-Myles, Gary Van Domselaar, Xuguang Li
Emerg Microbes Infect, 10.05.2023
Tilføjet 10.05.2023
19
Systematic review of the efficacy, effectiveness and safety of high‐dose seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
Laura Comber; Eamon O Murchu; Karen Jordan; Sarah Hawkshaw; Liam Marshall; Michelle O'Neill; Conor Teljeur; Máirín Ryan; AnnaSara Carnahan; Jaime Jesús Pérez Martín; Anna Hayman Robertson; Kari Johansen; Jorgen Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Patricia Harrington;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
This review sought to assess the efficacy, effectiveness and safety of high‐dose inactivated influenza vaccines (HD‐IIV) for the prevention of laboratory‐confirmed influenza in individuals aged 18 years or older. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non‐randomised studies of interventions (NRSIs) were included. The search returned 28,846 records, of which 36 studies were included. HD‐IIV was shown to have higher relative vaccine efficacy in preventing influenza compared with standard‐dose influenza vaccines (SD‐IIV3) in older adults (Vaccine effectiveness (VE) = 24%, 95% CI 10–37, one RCT). One NRSI demonstrated significant effect for HD‐IIV3 against influenza B (VE = 89%, 95% CI 47–100), but not for influenza A(H3N2) (VE = 22%, 95% CI −82 to 66) when compared with no vaccination in older adults. HD‐IIV3 showed significant relative effect compared with SD‐IIV3 for influenza‐related hospitalisation (VE = 11.8%, 95% CI 6.4–17.0, two NRSIs), influenza‐ or pneumonia‐related hospitalisation (VE = 13.7%, 95% CI 9.5–17.7, three NRSIs), influenza‐related hospital encounters (VE = 13.1%, 95% CI 8.4–17.7, five NRSIs), and influenza‐related office visits (VE = 3.5%, 95% CI 1.5–5.5, two NRSIs). For safety, HD‐IIV were associated with significantly higher rates of local and systemic adverse events compared with SD‐IIV (combined local reactions, pain at injection site, swelling, induration, headache, chills and malaise). From limited data, compared with SD‐IIV, HD‐IIV were found to be more effective in the prevention of laboratory‐confirmed influenza, for a range of proxy outcome measures, and associated with more adverse events.
Læs mere
Tjek på PubMed
20
Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
Eamon O Murchu; Laura Comber; Karen Jordan; Sarah Hawkshaw; Liam Marshall; Michelle O’Neill; Máirín Ryan; Conor Teljeur; Annasara Carnahan; Jaime Jesús Pérez; Anna Hayman Robertson; Kari Johansen; Jorgen de Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Patricia Harrington;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of MF59 adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory‐confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non‐randomised studies of interventions (NRSIs) were eligible for inclusion. The search returned 28,846 records, of which 48 studies on MF59 adjuvanted vaccines met our inclusion criteria. No efficacy trials were identified. In terms of vaccine effectiveness (VE), MF59 adjuvanted trivalent influenza vaccines were effective in preventing laboratory‐confirmed influenza in older adults (aged ≥65 years) compared with no vaccination (VE = 45%, 95% confidence interval (CI) 23%–61%, 5 NRSIs across 3 influenza seasons). By subtype, significant effect was found for influenza A(H1N1) (VE = 61%, 95% CI 44%–73%) and B (VE = 29%, 95% CI 5%–46%), but not for A(H3N2). In terms of relative VE, there was no significant difference comparing MF59 adjuvanted trivalent vaccines with either non‐adjuvanted trivalent or quadrivalent vaccines. Compared with traditional trivalent influenza vaccines, MF59 adjuvanted trivalent influenza vaccines were associated with a greater number of local adverse events (RR = 1.90, 95% CI 1.50–2.39) and systemic reactions (RR = 1.18, 95% CI 1.02–1.38). In conclusion, MF59 adjuvanted trivalent influenza vaccines were found to be more effective than ‘no vaccination’. Based on limited data, there was no significant difference comparing the effectiveness of MF59 adjuvanted vaccines with their non‐adjuvanted counterparts.
Læs mere
Tjek på PubMed
21
Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
Eamon O Murchu; Laura Comber; Karen Jordan; Sarah Hawkshaw; Liam Marshall; Michelle O’Neill; Máirín Ryan; Conor Teljeur; Annasara Carnahan; Jaime Jesús Pérez; Anna Hayman Robertson; Kari Johansen; Jorgen de Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Patricia Harrington;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of recombinant haemagglutinin (HA) seasonal influenza vaccines to prevent laboratory‐confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non‐randomised studies of interventions were eligible for inclusion. The search returned 28,846 records, of which 10 studies on recombinant HA influenza vaccine met our inclusion criteria. One study found that the quadrivalent recombinant HA influenza vaccine had higher relative vaccine efficacy (rVE) in preventing laboratory‐confirmed influenza during the 2014–15 season compared with traditional quadrivalent vaccination in adults aged ≥50 years (rVE = 30%, 95% CI 10%–47%, moderate‐certainty evidence). In a subgroup analysis, higher rVE was reported for influenza A (rVE = 36%, 95% CI 14% to 53%), but not for B (non‐significant). Another study reported higher efficacy for the trivalent recombinant HA vaccine compared with placebo (VE = 45%, 95% CI 19–63, 1 RCT, low‐certainty evidence) in adults aged 18–55 years. With the exception of a higher rate of chills (RR = 1.33, 95% CI 1.03–1.72), the safety profile of recombinant HA vaccines was comparable to that of traditional influenza vaccines. The evidence base for the efficacy and effectiveness of recombinant HA influenza vaccines is limited at present, although one study found that the quadrivalent recombinant HA influenza vaccine had higher rVE compared with traditional quadrivalent vaccination in adults aged ≥50 years.
Læs mere
Tjek på PubMed
22
Systematic review of the efficacy, effectiveness and safety of cell‐based seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
Karen Jordan; Eamon O. Murchu; Laura Comber; Sarah Hawkshaw; Liam Marshall; Michelle O’Neill; Conor Teljeur; Patricia Harrington; Annasara Carnahan; Jaime Jesús Pérez‐Martín; Anna Hayman Robertson; Kari Johansen; Jorgen de Jonge; Tyra Krause; Nathalie Nicolay; Hanna Nohynek; Ioanna Pavlopoulou; Richard Pebody; Pasi Penttinen; Marta Soler‐Soneira; Ole Wichmann; Máirín Ryan;
Reviews in Medical Virology, 10.05.2023
Tilføjet 10.05.2023
The most effective means of preventing seasonal influenza is through strain‐specific vaccination. In this study, we investigated the efficacy, effectiveness and safety of cell‐based trivalent and quadrivalent influenza vaccines. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non‐randomised studies of interventions (NRSIs) were eligible for inclusion. Two reviewers independently screened, extracted data and assessed the risk of bias of included studies. Certainty of evidence for key outcomes was assessed using the GRADE methodology. The search returned 28,846 records, of which 868 full‐text articles were assessed for relevance. Of these, 19 studies met the inclusion criteria. No relative efficacy data were identified for the direct comparison of cell‐based vaccines compared with traditional vaccines (egg‐based). Efficacy data were available comparing cell‐based trivalent influenza vaccines with placebo in adults (aged 18–49 years). Overall vaccine efficacy was 70% against any influenza subtype (95% CI 61%–77%, two RCTS), 82% against influenza A(H1N1) (95% CI 71%–89%, 2 RCTs), 72% against influenza A(H3N2) (95% CI 39%–87%, 2 RCTs) and 52% against influenza B (95% CI 30%–68%, 2 RCTs). Limited and heterogeneous data were presented for effectiveness when compared with no vaccination. One NRSI compared cell‐based trivalent and quadrivalent vaccination with traditional trivalent and quadrivalent vaccination, finding a small but significant difference in favour of cell‐based vaccines for influenza‐related hospitalisation, hospital encounters and physician office visits. The safety profile of cell‐based trivalent vaccines was comparable to traditional trivalent influenza vaccines. Compared with placebo, cell‐based trivalent influenza vaccines have demonstrated greater efficacy in adults aged 18–49 years. Overall cell‐based vaccines are well‐tolerated in adults, however, evidence regarding the effectiveness of these vaccines compared with traditional seasonal influenza vaccines is limited.
Læs mere
Tjek på PubMed
23
Burden of respiratory viruses in children less than two years in a community-based longitudinal U.S. birth cohort
Clinical Infectious Diseases, 9.05.2023
Tilføjet 9.05.2023
AbstractBackgroundRespiratory viral infections are a major cause of morbidity and hospitalization in young children. Nevertheless, the population burden of respiratory viral infections, especially asymptomatic cases, is not known due to the lack of prospective community-based cohort studies with intensive monitoring.MethodsTo address this gap, we enacted the PREVAIL cohort, a CDC-sponsored birth cohort in Cincinnati, Ohio where children were followed from birth to 2 years of age. Weekly text surveys were administered to mothers to record acute respiratory illnesses (ARIs), which were defined as the presence of cough or fever (≥38oC). Weekly mid-turbinate nasal swabs were collected and tested using the Luminex Respiratory Pathogen Panel, which detected 16 viral pathogens. Viral infection was defined as one or more positive tests from the same virus or viral subtype within 30 days of previous positive. Maternal report and medical chart abstractions identified health care utilization.ResultsFrom 4/2017 to 7/2020, 245 mother-infant pairs were recruited and followed. From the 13,781 nasal swabs tested, a total of 2,211 viral infections were detected, of which, 821 (37%) were symptomatic. Children experienced 9.4 respiratory viral infections/child-year; half were rhinovirus/enterovirus. Viral ARI incidence was 3.3 episodes/child-year. Emergency department visits or hospitalization occurred with only 15% of respiratory syncytial virus infections, 10% of influenza infections, and only 4% of all viral infections. Regardless of pathogen, most infections were asymptomatic or mild.ConclusionsRespiratory viral infections are common in children 0-2 years. Most viral infections are asymptomatic or non-medically attended, underscoring the importance of community-based cohort studies.
Læs mere
Tjek på PubMed
24
Addressing influenza’s underestimated burden – Iberian experts call to action
BMC Infectious Diseases, 9.05.2023
Tilføjet 9.05.2023
Abstract Having a proper understanding of the impact of influenza is a fundamental step towards improved preventive action. This paper reviews findings from the Burden of Acute Respiratory Infections study on the burden of influenza in Iberia, and its potential underestimation, and proposes specific measures to lessen influenza’s impact.
Læs mere
Tjek på PubMed
25
Candidate historical events for the emergence of Human Coronavirus OC43: A critical reassessment of the molecular evidence
Brandon Shaw, Derek Gatherer
PLoS One Infectious Diseases, 9.05.2023
Tilføjet 9.05.2023
by Brandon Shaw, Derek Gatherer The “Russian Influenza”-coronavirus theory (RICT) proposes that the pandemic of 1889–1892, conventionally regarded as an influenza pandemic, was caused by the emergence of human coronavirus OC43 (HCoV-OC43) as a zoonosis of bovine coronavirus (BCoV). RICT is based on a Bayesian phylogenetic calculation of the date of the most recent common ancestor (MRCA) of HCoV-OC43 and BCoV. The theory also draws on comparison of both symptoms and some epidemiological parameters of the best studied coronavirus pandemic, i.e. COVID-19, with those reported in 1889–1892. The case is completed with circumstantial evidence involving a panzoonotic among cattle in the decade prior to the “Russian Influenza”, with characteristics suggesting it may have been caused by BCoV. In this paper, we review the Bayesian phylogenetic evidence for RICT, replicating previous studies and adding our own, in each case critically reviewing the suitability of the datasets used and the parameters applied. We conclude that the most probable date for the MRCA of HCoV-OC43 and BCoV is 1898–1902. This is a decade too late for compatibility with RICT but happens to coincide with another serious outbreak of respiratory illness, reported in both the USA and the UK, in the winter of 1899–1900.
Læs mere
Tjek på PubMed
26
A discrete-time susceptible-infectious-recovered-susceptible model for the analysis of influenza data
Infectious Disease Modelling, 7.05.2023
Tilføjet 7.05.2023
Publication date: Available online 6 May 2023 Source: Infectious Disease Modelling Author(s): Georges Bucyibaruta, C.B. Dean, Mahmoud Torabi
Læs mere
Tjek på PubMed
27
Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells
Namita Varudkar, Elisabeth M. Shiffer, Jeremiah L. Oyer, Alicja Copik, Griffith D. Parks
PLoS One Infectious Diseases, 5.05.2023
Tilføjet 5.05.2023
by Namita Varudkar, Elisabeth M. Shiffer, Jeremiah L. Oyer, Alicja Copik, Griffith D. Parks Antibody-dependent cellular cytotoxicity (ADCC) is one of the most powerful mechanisms for Natural Killer (NK) cells to kill cancer cells or virus-infected cells. A novel chimeric protein (NA-Fc) was created, which when expressed in cells, positions an IgG Fc domain on the plasma membrane, mimicking the orientation of IgG bound to the cell surface. This NA-Fc chimera was tested with PM21-NK cells, produced through a previously developed particle-based method which yields superior NK cells for immunotherapeutic applications. Real time viability assays revealed higher PM21-NK killing of both ovarian and lung cancer cells expressing NA-Fc, which correlated with increased release of TNF-α and IFN-γ cytokines from NK cells and was dependent on CD16-Fc interactions. Lentivirus delivery of NA-Fc to target cells increased the rate of PM21-NK cell killing of A549 and H1299 lung, SKOV3 ovarian and A375 melanoma cancer cells. This NA-Fc-directed killing was extended to virus infected cells, where delivery of NA-Fc to lung cells that were persistently infected with Parainfluenza virus resulted in increased killing by PM21-NK cells. In contrast to its effect on PM21-NK cells, the NA-Fc molecule did not enhance complement mediated lysis of lung cancer cells. Our study lays the foundation for application of the novel NA-Fc chimera that could be delivered specifically to tumors during oncolytic virotherapy to mark target cells for ADCC by co-treatment with adoptive NK cells. This strategy would potentially eliminate the need to search for unique cancer specific antigens for development of new antibody therapeutics.
Læs mere
Tjek på PubMed
28
[Articles] Wastewater concentrations of human influenza, metapneumovirus, parainfluenza, respiratory syncytial virus, rhinovirus, and seasonal coronavirus nucleic-acids during the COVID-19 pandemic: a surveillance study
Alexandria B Boehm, Bridgette Hughes, Dorothea Duong, Vikram Chan-Herur, Anna Buchman, Marlene K Wolfe, Bradley J White
The Lancet Microbe, 4.05.2023
Tilføjet 4.05.2023
Wastewater-based epidemiology can be used to obtain information on circulation of respiratory viruses at a localised, community level without the need to test many individuals because a single sample of wastewater represents the entire contributing community. Results from wastewater can be available within 24 h of sample collection, generating real time information to inform public health responses, clinical decision making, and individual behaviour modifications.
Læs mere
Tjek på PubMed
29
Comparison of Clinical Characteristics and Peripheral Blood Tests of COVID-19 and Influenza B Patients
American Journal of Tropical Medicine and Hygiene, 3.05.2023
Tilføjet 3.05.2023
Journal Name: The American Journal of Tropical Medicine and Hygiene Volume: 108 Issue: 5 Pages: 1028-1030
Læs mere
Tjek på PubMed
30
Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence
Ning Ma, Zhi-Wu Xia, Zhe-Gang Zhang, Xuan-Xuan Nian, Xue-Dan Li, Zheng Gong, Guo-Mei Zhang, Yang Le, Rong Zhou, Jia-You Zhang, Xiao-Ming Yang
Emerg Microbes Infect, 2.05.2023
Tilføjet 2.05.2023
31
Viral meningitis and encephalitis: an update
Gundamraj, Vaishnavi; Hasbun, Rodrigo
Current Opinion in Infectious Diseases, 1.05.2023
Tilføjet 1.05.2023
Purpose of review The most common infectious etiologies of meningitis and encephalitis are viruses. In this review, we will discuss current epidemiology, prevention, diagnosis, and treatment of the most common causes of viral meningitis and encephalitis worldwide. Recent findings Viral meningitis and encephalitis are increasingly diagnosed as molecular diagnostic techniques and serologies have become more readily available worldwide but recent progress in novel antiviral therapies remains limited. Emerging and re-emerging viruses that have caused endemic or worldwide outbreaks or epidemics are arboviruses (e.g., West Nile virus, Japanese encephalitis, Tick borne encephalitis, Dengue, Zika, Toscana), enteroviruses (e.g., Enterovirus 71, Enterovirus D68), Parechoviruses, respiratory viruses [e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, metapneumoviruses, measles, mumps], and herpes viruses [e.g., herpes simplex virus (HSV) type 1 (HSV-1), HSV-2, human herpes (HV) 6, varicella zoster virus (VZV)]. Future efforts should concentrate in increasing availability for those viruses with effective vaccination [e.g., Japanese encephalitis, Tick borne encephalitis, varicella zoster viruses, SARS-CoV-2, influenza], prompt initiation of those with encephalitis with treatable viruses (e.g., HSV-1, VZV), increasing the diagnostic yield by using novel techniques such as metagenomic sequencing and avoiding unnecessary antibiotics in those with viral meningitis or encephalitis. Summary We review the current epidemiology, clinical presentation, diagnosis, and treatment of the common causative agents of viral meningitis and encephalitis worldwide.
Læs mere
Tjek på PubMed
32
SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection
Clinical & Experimental Immunology, 29.04.2023
Tilføjet 29.04.2023
AbstractPost-acute cardiac sequelae, following SARS-CoV-2 infection, are well recognised as complications of COVID-19. We have previously shown the persistence of autoantibodies against antigens in skin, muscle, and heart in individuals following severe COVID-19; the most common staining on skin tissue displayed an inter-cellular cement pattern consistent with antibodies against desmosomal proteins. Desmosomes play a critical role in maintaining the structural integrity of tissues. For this reason, we analysed desmosomal protein levels and the presence of anti-desmoglein (DSG) 1, 2 and 3 antibodies in acute and convalescent sera from patients with COVID-19 of differing clinical severity. We find increased levels of DSG2 protein in sera from acute COVID-19 patients. Furthermore, we find that DSG2 autoantibody levels are increased significantly in convalescent sera following severe COVID-19 but not in hospitalised patients recovering from influenza infection or healthy controls. Levels of autoantibody in sera from patients with severe COVID-19 were comparable to levels in patients with non-COVID-19-associated cardiac disease, potentially identifying DSG2 autoantibodies as a novel biomarker for cardiac damage. To determine if there was any association between severe COVID-19 and DSG2, we stained post-mortem cardiac tissue from patients who died from COVID-19 infection. This confirmed DSG2 protein within the intercalated discs and disruption of the intercalated disc between cardiomyocytes in patients who died from COVID-19. Our results reveal the potential for DSG2 protein and autoimmunity to DSG2 to contribute to unexpected pathologies associated with COVID-19 infection.
Læs mere
Tjek på PubMed
33
TGM2 inhibits the proliferation, migration and tumorigenesis of MDCK cells
Zhenyu Qiu, Shouqing Guo, Geng Liu, Mengyuan Pei, Yuejiao Liao, Jiamin Wang, Jiayou Zhang, Di Yang, Zilin Qiao, Zhuo Li, Zhongren Ma, Zhenbin Liu, Xiaoming Yang
PLoS One Infectious Diseases, 28.04.2023
Tilføjet 28.04.2023
by Zhenyu Qiu, Shouqing Guo, Geng Liu, Mengyuan Pei, Yuejiao Liao, Jiamin Wang, Jiayou Zhang, Di Yang, Zilin Qiao, Zhuo Li, Zhongren Ma, Zhenbin Liu, Xiaoming Yang Madin-Darby canine kidney (MDCK) cells are one of the main cell lines used for influenza vaccine production due to their high virus yield and low mutation resistance. Due to their high tumorigenicity, the safety of vaccines produced from these cells is controversial. TGM2 is a multifunctional protein that plays an important role in the adhesion and migration of cells and is associated with tumor formation. We found that the expression level of TGM2 was significantly up-regulated in low tumorigenic MDCK cells. We first analyzed TGM2-overexpressed and knockout MDCK cells in vitro. Scratch-wound assay and Transwell chamber experiments showed that TGM2 overexpression significantly inhibited the migration and invasion of MDCK cells and significantly reduced their proliferation. TGM2 knockout significantly enhanced cell migration, invasion, and proliferation. The tumorigenesis results in nude mice were consistent with those in vitro. TGM2 knockout significantly enhanced the tumorigenesis rate of MDCK cells in nude mice. We also investigated the effects of TGM2 gene expression on the replication of the H1N1 influenza A virus in MDCK cells. The results showed that TGM2 induced the negative regulation of H1N1 replication. These findings contribute to a comprehensive understanding of the tumor regulation mechanism and biological functions of TGM2.
Læs mere
Tjek på PubMed
34
Detection of H275Y oseltamivir resistance gene mutation among Influenza A(H1N1)pdm09 patients by allelic discrimination real‐time RT‐PCR
Smriti Krishna, Anup Jayaram, Ujwal Shetty, Prasad Varamballi, Chiranjay Mukhopadhyay, Anitha Jagadesh
Journal of Medical Virology, 28.04.2023
Tilføjet 28.04.2023
35
History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case-control study
Ritsinger, V., Bodegard, J., Kristofi, R., Thuresson, M., Nathanson, D., Nyström, T., Eriksson, J., Norhammar, A.
BMJ Open, 28.04.2023
Tilføjet 28.04.2023
ObjectivesTo explore how cardiorenal disease (CRD; heart failure and/or chronic kidney disease) impacted mortality in men and women hospitalised for COVID-19 during the first three waves of the pandemic in Sweden in comparison to previous influenza outbreaks. DesignA registry-based, retrospective, case–control study. SettingHospital care in Sweden. ParticipantsAll patients in Sweden with a main hospital diagnosis of COVID-19 (January 2020–September 2021) or influenza (January 2015–December 2019) with previous CRD were identified in registries and compared with a reference group free from CRD but with COVID-19 or influenza. Primary outcome measureAssociated risk of all-cause death during the first year was analysed using adjusted Cox proportional hazards models. ResultsIn COVID-19 patients with and without prior history of CRD (n=44 866), mean age was 79.8 years (SD 11.8) and 43% were women. In influenza patients (n=8897), mean age was 80.6 years (SD 11.5) and 45% were women. COVID-19 versus influenza was associated with higher mortality risk during the first two COVID-19 waves (HR 1.53; 95% CI 1.45 to 1.62, p
Læs mere
Tjek på PubMed
36
Ethanol vapor inhalation treatment inhibits lethal respiratory viral infection with Influenza A
Journal of Infectious Diseases, 27.04.2023
Tilføjet 27.04.2023
AbstractEthanol (EtOH) effectively inactivates enveloped viruses in vitro, including influenza and SARS-CoV-2. Inhaled EtOH vapor may inhibit viral infection in mammalian respiratory tracts, but this has not yet been demonstrated. Here we report that unexpectedly low EtOH concentrations in solution, approximately 20% (v/v), rapidly inactivate influenza A virus (IAV) at mammalian body temperature (37°C) and are not toxic to lung epithelial cells upon apical exposure. Furthermore, brief exposure to 20% (v/v) EtOH decreases production of infectious progeny viruses in IAV-infected cells. Using an EtOH vapor exposure system that is expected to expose murine respiratory tracts to 20% (v/v) EtOH solution by gas-liquid equilibrium at 37°C, we demonstrate that brief EtOH vapor inhalation twice a day protects mice from lethal IAV respiratory infection by reducing viruses in the lungs without harmful side effects. Our data suggest that EtOH vapor inhalation may provide a versatile therapy against various respiratory viral infectious diseases.
Læs mere
Tjek på PubMed
37
Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies
Chung-Young LeeVedhika RaghunathanC. Joaquin CaceresGinger GeigerBrittany SeibertFlavio Cargnin FaccinL. Claire GayLucas M. FerreriDrishti KaulJens WrammertGene S. TanDaniel R. PerezAnice C. LowenaDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322bDepartment of Microbiology, School of Medicine, Kyungpook National University, Daegu 41944, The Republic of KoreacDepartment of Population Health, College of Veterinary Medicine, University of Georgia, Athens, GA 30602dJ. Craig Venter Institute, La Jolla, CA 92037eDivision of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322fDivision of Infectious Disease, Department of Medicine, University of California San Diego, La Jolla, CA 92093gEmory-University of Georgia Center of Excellence for Influenza Research and Surveillance, Atlanta, GA 30322
Proceedings of the National Academy of Sciences, 26.04.2023
Tilføjet 26.04.2023
38
Bayesian phylodynamics reveals the transmission dynamics of avian influenza A(H7N9) virus at the human–live bird market interface in China
Claire GuinatHao TangQiqi YangCecilia Valenzuela AgüíTimothy G. VaughanJérémie ScireHongjie YuWei WangZhiyuan ChenMariette F. DucatezTanja StadleraDepartment of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, SwitzerlandbSwiss Institute of Bioinformatics, 1015 Lausanne, SwitzerlandcCentre for Biosecurity and One Health, Harry Butler Institute, Murdoch University, Murdoch, WA 6150, AustraliadDepartment of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ 08544eSchool of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, 200032 Shanghai, ChinafUnit of Host-Pathogens Interactions, University of Toulouse, National Research Institute for Agriculture, Food and the Environment, National Veterinary School of Toulouse, 31300 Toulouse, France
Proceedings of the National Academy of Sciences, 26.04.2023
Tilføjet 26.04.2023
39
Prevalence, evolution, replication and transmission of H3N8 avian influenza viruses isolated from migratory birds in eastern China from 2017 to 2021
Yanwen Wang, Mengjing Wang, Hong Zhang, Conghui Zhao, Yaping Zhang, Jinyan Shen, Xiaohong Sun, Hongke Xu, Yujiao Xie, Xinxin Gao, Pengfei Cui, Dong Chu, Yubao Li, Wenqiang Liu, Peng Peng, Guohua Deng, Jing Guo, Xuyong Li
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
40
Cross-species infection potential of avian influenza H13 viruses isolated from wild aquatic birds to poultry and mammals
Weiyang Sun, Menglin Zhao, Zhijun Yu, Yuanguo Li, Xinghai Zhang, Na Feng, Tiecheng Wang, Hongmei Wang, Hongbin He, Yongkun Zhao, Songtao Yang, Xianzhu Xia, Yuwei Gao
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
41
Emerging triple-reassortant influenza C virus with household-associated infection during an influenza A(H3N2) outbreak, China, 2022
Lan Cao, Ying Lu, Chaojun Xie, Yiyun Chen, Lijun Liang, Tengfei Zhou, Ziyi Zeng, Chen Wen, Biao Di, Baisheng Li, Kuibiao Li, Zhoubin Zhang
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
42
Risk assessment of the newly emerged H7N9 avian influenza viruses
Pengxiang Chang, Jean-Remy Sadeyen, Sushant Bhat, Rebecca Daines, Altaf Hussain, Huseyin Yilmaz, Munir Iqbal
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
43
Highly pathogenic avian influenza H5N1 virus outbreak among Cape cormorants (Phalacrocorax capensis) in Namibia, 2022
Umberto Molini, John Yabe, Irene K. Meki, Hatem Ouled Ahmed Ben Ali, Tirumala B. K. Settypalli, Sneha Datta, Lauren Michelle Coetzee, Ellini Hamunyela, Siegfried Khaiseb, Giovanni Cattoli, Charles E. Lamien, William G. Dundon
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
44
Influenza viral infection is a risk factor for severe illness in COVID-19 patients: a nationwide population-based cohort study
Jeong-Hwan Hwang, Yeon Seok You, Sang Woo Yeom, Min Gyu Lee, Jong-hwan Lee, Min Gul Kim, Jong Seung Kim
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
45
Influenza vaccination is associated with a reduced risk of invasive aspergillosis in high-risk individuals in Taiwan: a population-based cohort study
Yi-Jyun Chen, I-Feng Lin, Jen-Hsiang Chuang, Hung-Ling Huang, Ta-Chien Chan
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
46
Alarming situation of emerging H5 and H7 avian influenza and effective control strategies
Jianzhong Shi, Xianying Zeng, Pengfei Cui, Cheng Yan, Hualan Chen
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
47
Epidemiology, evolution, and biological characteristics of H6 avian influenza viruses in China
Xiaohao Xu, Qi Chen, Min Tan, Jia Liu, Xiyan Li, Lei Yang, Yuelong Shu, Dayan Wang, Wenfei Zhu
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
48
Genetic, biological and epidemiological study on a cluster of H9N2 avian influenza virus infections among chickens, a pet cat, and humans at a backyard farm in Guangxi, China
Jing Yang, Jianhua Yan, Cheng Zhang, Shanqin Li, Manhua Yuan, Chunge Zhang, Chenguang Shen, Yang Yang, Lifeng Fu, Guanlong Xu, Weifeng Shi, Zhenghai Ma, Ting Rong Luo, Yuhai Bi
Emerg Microbes Infect, 24.04.2023
Tilføjet 24.04.2023
49
Comparing the transmission potential from sequence and surveillance data of 2009 North American influenza pandemic waves
Infectious Disease Modelling, 24.04.2023
Tilføjet 24.04.2023
Publication date: March 2023 Source: Infectious Disease Modelling, Volume 8, Issue 1 Author(s): Venkata R. Duvvuri, Joseph T. Hicks, Lambodhar Damodaran, Martin Grunnill, Thomas Braukmann, Jianhong Wu, Jonathan B. Gubbay, Samir N. Patel, Justin Bahl
Læs mere
Tjek på PubMed
50
Epidemiological, serological, and genetic evidence of influenza D virus infection in humans: Is it a justifiable cause for concern?
Widaliz Vega-Rodriguez, Hinh Ly
Virulence, 24.04.2023
Tilføjet 24.04.2023